CYP2C19 Polymorphism in Patients with Gastroesophageal Reflux Disease - a Pilot Study

Background. Gastroesophageal reflux disease (GERD) is a disease of modern civilization whose symptoms occur in 5-10% of individuals living in Western countries. Proton pump inhibitors (PPIs) are the basis of the medical treatment of GERD. PPIs are metabolized with the system of enzymes of cytochrome P450. Polymorphism of the isoenzymes comprising this system determines the different speeds of the metabolism of the drugs. Objectives. The aim of the study was the analysis of CYP2C19 polymorphism in GERD patients in relation to the presence of GERD complications. Material and Methods. The study group consisted of 40 patients hospitalized in the Department of Gastroenterology and Hepatology of Wroclaw Medical University with a diagnosis of GERD and 17 patients treated surgically in the Clinic of Gastrointestinal and General Surgery of Wroclaw Medical University due to GERD complications. Two SNP-type polymorphisms in gene CYP2C19 were studied with the PCR-RFLP (polymerase chain reaction, restriction fragment length polymorphism) method. Results. Most of the patients were found to belong to the phenotype of extensive metabolizers (EM). Genotypes and frequency of the alleles of polymorphism 681G -> A in gene CYP2C19 in GERD patient groups with and without complications are shown in table 2. Conclusions. Most of the patients with uncomplicated GERD belong to the phenotype of extensive metabolizers (EM). Our results do not suggest that the polymorphism of gene CYP2C19 plays a role in the development of severe GERD complications (Adv Clin Exp Med 2011, 20, 1, 65-69).